In pursuit of safer controlled-deactivation cannabinoids with high
potency and short duration of action, we report the design, synthesis, and
pharmacological evaluation of novel C9- and C11-hydroxy-substituted
hexahydrocannabinol (HHC) and tetrahydrocannabinol (THC) analogues in which a
seven atom long side chain, with or without 1′-substituents, carries a
metabolically labile 2′,3′-ester group. Importantly, in vivo
studies validated our controlled deactivation approach in rodents and non-human
primates. The lead molecule identified here, namely,
butyl-2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydro-6H-benzo[c]chromen-3-yl]-2-methylpropanoate
(AM7499), was found to exhibit remarkably high in vitro and in vivo potency with
shorter duration of action than the currently existing classical cannabinoid
agonists.